The department has developed and produced 15 different formulations for early clinical trials (
e.g. vaccine antigens produced by heterologous expression) and has conducted more than 20 clinical trials as sponsor.
Not exact matches
Commercial arrays are not available for all biomarkers, so customised arrays for the analysis of
vaccine candidates will be developed, featuring
antigens for direct detection or antibodies for sandwich immunoassays (
e.g. for cytokine detection).
Currently, pDNA can be used directly as a therapeutic agent (
e.g., in gene therapy or generation of
vaccine antigens) and indirectly for a range of applications.
There is no evidence in Marek's disease that
vaccine breakthrough by more virulent strains has anything to do with overcoming strain - specific immunity (
e.g., epitope evolution); genetic and immunological comparisons of strains varying in virulence suggest that candidate virulence determinants are associated with host — cell interactions and viral replication, not
antigens [19].